Neuroendocrine Tumor G3 — Trials

Neuroendocrine Tumor G3 — Trials · CancerIndex

Clinical trials

Registered studies

3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05973968	Surufatinib in G3 Neuroendocrine Tumors	unknown	—	32	Qilu Hospital of Shandong UniversityOTHER	0	Aug 4, 2023	clinicaltrials
NCT05627427	Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy	unknown	Phase 2	60	Tianjin Medical University Cancer Institute and HospitalOTHER	1	Nov 25, 2022	clinicaltrials
NCT05113355	Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm	unknown	Phase 2	23	Peking Union Medical College HospitalOTHER	1	Nov 24, 2021	clinicaltrials

Data updated 22 days agoSource updated Aug 4, 2023source: clinicaltrials